Quick Takeaways
- Jean J. Bienaime has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $57,757,623.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Jean J. Bienaime
- Location
- Palo Alto, CA
- Summary
- The estimated net worth of Jean J. Bienaime is at least $57,757,623 dollars as of 01 Apr 2026. Jean J. Bienaime is the Director of BIOMARIN PHARMACEUTICAL INC and owns shares of BIOMARIN PHARMACEUTICAL INC (BMRN) stock worth about $55.58M. Jean J. Bienaime is the Director of INCYTE CORP and owns shares of INCYTE CORP (INCY) stock worth about $1.27M. Jean J. Bienaime is the Director of Immunome Inc. and owns shares of Immunome Inc. (IMNM) stock worth about $827.8K. Jean J. Bienaime is the Director of Keros Therapeutics, Inc. and owns shares of Keros Therapeutics, Inc. (KROS) stock worth about $83.5K.
- Signature
- /s/ Michael Wolff Jensen as attorney-infact for Jean J Bienaime
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Jean J. Bienaime and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: BIOMARIN PHARMACEUTICAL INC ($55,578,092).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Jean J. Bienaime
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| BMRN | BIOMARIN PHARMACEUTICAL INC | Director | $55,578,092 | 20 May 2024 | ||
| INCY | INCYTE CORP | Director | $1,268,174 | 10 Jun 2025 | ||
| IMNM | Immunome Inc. | Director | $827,843 | +$90,570 | +12% | 10 Mar 2026 |
| KROS | Keros Therapeutics, Inc. | Director | $83,514 | +$22,420 | +37% | 09 Mar 2026 |
| ASND | Ascendis Pharma A/S | Director | $0 | 23 Mar 2026 |
Insider Transactions Reported by Jean J. Bienaime:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.